Account-creators
1,040
edits
Jensflorian (talk | contribs) (→General: Outdated terminology) |
Jensflorian (talk | contribs) m (→General: typos) |
||
Line 36: | Line 36: | ||
*Called the forgotten glial tumour. | *Called the forgotten glial tumour. | ||
*Anatomic location is essential for tumor diagnosis. | *Anatomic location is essential for tumor diagnosis. | ||
Epidemiology:<ref name=Ref_PBoD8_1334>{{Ref PBoD8|1334}}</ref> | Epidemiology:<ref name=Ref_PBoD8_1334>{{Ref PBoD8|1334}}</ref> | ||
Line 42: | Line 43: | ||
**Children: usually posterior fossa. | **Children: usually posterior fossa. | ||
*May be associated with [[neurofibromatosis type 2]]. | *May be associated with [[neurofibromatosis type 2]]. | ||
There are currently eight main ependymal tumors:<ref name=Ref_WHOCNS_74>{{Ref WHOCNS|74}}</ref> | There are currently eight main ependymal tumors:<ref name=Ref_WHOCNS_74>{{Ref WHOCNS|74}}</ref> | ||
Line 53: | Line 55: | ||
#[[Subependymoma]] | #[[Subependymoma]] | ||
Ependymoma(not otherwise specified). | Ependymoma (not otherwise specified). | ||
*Depreceated terminologies: | *Depreceated terminologies: | ||
Line 60: | Line 62: | ||
**Tanycytic ependymoma. | **Tanycytic ependymoma. | ||
**Cellular ependymoma. | **Cellular ependymoma. | ||
**Ependymoma, RELA fusion-positive.<ref>{{Cite journal | last1 = Parker | first1 = M. | last2 = Mohankumar | first2 = KM. | last3 = Punchihewa | first3 = C. | last4 = Weinlich | first4 = R. | last5 = Dalton | first5 = JD. | last6 = Li | first6 = Y. | last7 = Lee | first7 = R. | last8 = Tatevossian | first8 = RG. | last9 = Phoenix | first9 = TN. | title = C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. | journal = Nature | volume = 506 | issue = 7489 | pages = 451-5 | month = Feb | year = 2014 | doi = 10.1038/nature13109 | PMID = 24553141 }}</ref> | **Ependymoma, RELA fusion-positive.<ref>{{Cite journal | last1 = Parker | first1 = M. | last2 = Mohankumar | first2 = KM. | last3 = Punchihewa | first3 = C. | last4 = Weinlich | first4 = R. | last5 = Dalton | first5 = JD. | last6 = Li | first6 = Y. | last7 = Lee | first7 = R. | last8 = Tatevossian | first8 = RG. | last9 = Phoenix | first9 = TN. | title = C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. | journal = Nature | volume = 506 | issue = 7489 | pages = 451-5 | month = Feb | year = 2014 | doi = 10.1038/nature13109 | PMID = 24553141 }}</ref><ref>{{Cite journal | last1 = Pietsch | first1 = T. | last2 = Wohlers | first2 = I. | last3 = Goschzik | first3 = T. | last4 = Dreschmann | first4 = V. | last5 = Denkhaus | first5 = D. | last6 = Dörner | first6 = E. | last7 = Rahmann | first7 = S. | last8 = Klein-Hitpass | first8 = L. | title = Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signaling pathway. | journal = Acta Neuropathol | volume = 127 | issue = 4 | pages = 609-11 | month = Apr | year = 2014 | doi = 10.1007/s00401-014-1264-4 | PMID = 24562983 }}</ref> This is now called Supratentorial ependymoma, ZFTA-fusion positive. | ||
**Anaplastic ependymoma. | **Anaplastic ependymoma. | ||